Seqirus announces $140M expansion of Holly Springs flu vaccine facility

Seqirus, a CSL subsidiary, announced a $140 million expansion of its Holly Springs manufacturing facility in North Carolina to increase capacity for formulation, fill and finish of cell-based and adjuvanted influenza vaccines. The expansion will create 120 permanent jobs and is expected to be complete by 2020.

“We are deeply committed to developing innovative solutions, including cell-based vaccines, to help reduce deaths and severe illness caused by influenza.”newsroom.csl.com

• 2 sources
• newsroom.csl.comNews Releases | CSLNov 16, 2018
• prnewswire.comSeqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza VaccinesSeqirusNov 16, 2018

Summarized from public sources; check the original articles before acting on it.